4 Results for "

hepatic ballooning

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "hepatic ballooning" in MCE Product Catalog:

Referencia número: HY-172661
No. CAS: 2661053-09-2
Kylo-0603 is an orally active thyroid hormone receptor β (THR-β) agonist with an EC50 of 31.07 nM against human targets, and it exhibits much higher selectivity for THR-β than for THR-α. Kylo-0603 enables hepatocyte-targeted delivery via GalNAc modification. Kylo-0603 reduces serum cholesterol and low-density lipoprotein cholesterol levels. Kylo-0603 alleviates hepatic steatosis, inflammatory responses, hepatocyte ballooning, and non-alcoholic steatohepatitis activity scores. Kylo-0603 inhibits the progression of hepatic fibrosis. Kylo-0603 can be used for research on metabolic dysfunction-associated steatohepatitis (MASH) .
loading...
    loading...
Referencia número: HY-167643
No. CAS: 1027597-04-1
Target:  

Drug Metabolite

Áreas de investigación:  

Metabolic Disease Inflammation/Immunology

Hydroxy tipelukast (Compound MN-002), the metabolite of Compound MN-001, is an orally active phenoxyalkylcarboxylic acid. Hydroxy tipelukast inhibits liver steatosis, lobular inflammation, hepatic ballooning, and hepatic scarring, and reduces liver hydroxyproline levels. Hydroxy tipelukast is promising for research of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) .
loading...
    loading...
Referencia número: HY-181896S
PPARγ agonist-23 (Compound 9) is an orally active PPARγ agonist with an EC50 of 0.32 μM. PPARγ agonist-23 improves hepatic triglyceride levels, reduces scores of steatosis and hepatocellular ballooning, and decreases the total activity score of non-alcoholic steatohepatitis (NASH). PPARγ agonist-23 can be used for the research of non-alcoholic steatohepatitis .
loading...
    loading...
Referencia número: HY-183279
Target:  

FXR AMPK

Áreas de investigación:  

Metabolic Disease

FXR antagonist 4 (Compound 4l) is an orally active, selective FXR antagonist with an IC50 of 0.70 μM. FXR antagonist 4 binds to FXR, differentially regulates bile acid and lipid transporter genes, and exerts no effect on gluconeogenesis-related genes. FXR modulator 1 activates the AMPK signaling pathway to inhibit fatty acid synthesis. FXR modulator 1 alleviates hepatic steatosis, ballooning degeneration and fibrosis, and improves dyslipidemia. FXR modulator 1 can be used for research on metabolic dysfunction-associated steatohepatitis .
loading...
    loading...